Revance Therapeutics reported $-70012000 in EBIT for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Adamas Pharmaceuticals ADMS:US -9525000 5.45M
Aerie Pharmaceuticals AERI:US $ -34219000 1.37M
ALKERMES ALKS:US -16432000 14.3M
Antares Pharma ATRS:US $ 5.39M 707K
Biodelivery Sciences International BDSI:US $ 7.44M 5.08M
Bristol Myers Squibb BMY:US $ 2556M 1406M
Cara Therapeutics CARA:US $ -23561000 101.85M
Eli Lilly And LLY:US $ 1666.2M 662.1M
Endo International Ordinary Shares ENDP:US $ 219.43M 43.78M
Flexion Therapeutics FLXN:US $ -23141000 8.84M
Gw Pharmaceuticals GWPH:US -21027000 1.78M
Horizon Pharma HZNP:US -89446000 326.97M
JAZZ PHA JAZZ:US 162.12M 11.3M
Johnson & Johnson JNJ:US $ 7580.4M 3038.4M
Merk MRK:US $ 4290M 4007M
Neurocrine Biosciences NBIX:US $ 31.5M 40.3M
Pacira Pharmaceuticals PCRX:US $ 21.31M 4.24M
Procter & Gamble PG:US $ 3919M 1953M
Revance Therapeutics RVNC:US $ -70012000 7.96M
Supernus Pharmaceuticals SUPN:US $ 13.21M 29.88M
Teva Pharmaceutical Industries TEVA:US 794M 12M